Transient Ischemic Attack (tia) Guideline Knowledge And Perceived Barriers To Implementation Amongst Emergency Department Health Care Providers In A Rural State

Transient Ischemic Attack (TIA) is a prominent risk factor for subsequent stroke, and its associated morbidity, mortality, and health care costs. Studies have demonstrated up to 80% reductions in subsequent stroke rate with prompt, optimized protocols for rapid TIA evaluation and treatment. National Stroke Association (NSA) and American Heart Association (AHA) guidelines have recommended institution of protocols assuring timely completion of the recommended testing, and evaluation by a stroke expert within 48 hours. However, limited literature exists on the implementation of guideline-based care in rural regions, and the few studies related to TIA suggest that barriers including difficulty accessing services and poorly updated TIA knowledge amongst rural, non-neurologist providers exist despite national guidelines. Behavior change theories have suggested that evaluating factors hindering or motivating behavior change may aid in tailoring implementation of guideline-based practices. This descriptive study sought to understand ED health care providers\u27 perceived barriers to implementation of NSA/AHA TIA guidelines in a rural state. All healthcare providers in each of the state\u27s emergency departments were invited by email to complete an online anonymous survey assessing knowledge of present TIA guidelines and perceived barriers to implementation of these guidelines in their practice setting using a modified Barriers and Facilitators Assessment Instrument (BFAI). After completing the knowledge based questions, respondents were presented a brief educational overview of the guidelines to ensure adequate familiarity with the TIA guidelines to complete the BFAI. Thirty-nine respondents completed the survey. Twenty-seven worked at regional or academic medical centers, and 12 worked at critical access hospitals representing the more rural regions of the state. Consistent with prior work, the most notable finding of this study was a low awareness of the present TIA guidelines amongst ED providers, with none of the survey respondents correctly identifying all items consistent with the evaluation guidelines for TIA. In addition to a low awareness of the guidelines, a number of perceived barriers to implementation were identified, which may inform efforts at implementation, and/or offer a model for similar barrier assessment elsewhere

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 Poster Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 Abstract Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 Project Plan Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 Midterm Report Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 IPRO Day Presentation Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

Synthetic Biology: Engineering a Novel Organism (semester?), IPRO 302: Synthetic Biology IPRO 302 Final Report Sp07

Synthetic biology is a relatively new approach to genetic research where the focus is to build a simple genetic system with known processes and test it in a biological setting. This is in contrast to the reductionist approach where a complex pre-existing biological system is analyzed in an attempt to discover the purpose of each of the parts. In this IPRO, a very simple genetic system is being designed, built, and tested in a biological setting. Previous semesters have already accomplished such in bacteria. This semester's focus will be on building the system designed last semester and inserting it into an eukaryotic organism; the zebrafish. The main purpose of this IPRO is to advance the knowledge of biological systems and their manipulation. This is being done through the design and creation of a simple, but novel, genetic circuit, and the introduction of this circuit into an organism to observe its properties in vivo. In order to accomplish this goal, we have split up into 4 different sub-teams: Fish, Math Modeling, Futures and Design, and ConstructionDeliverables for IPRO 302: Synthetic Biology: Engineering a Novel Organism for the Spring 2007 semeste

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit. To examine whether CoQ10 could slow disease progression in early PD. A phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation. The remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E. Participants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo. The baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66% of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo). Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit. clinicaltrials.gov Identifier: NCT00740714